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PMH49
PERFORMANCE OF THE SF-12 AND RAND-12
PHYSICAL AND MENTAL HEALTH SUMMARY
SCORES IN PEOPLE PRACTICING 
MEDITATION
Treesak C,Ye X, Sakthong P, Gross CR
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: Previous studies suggested that the per-
formance of RAND-36 summary scores was better than
that of the SF-36 in discriminating groups with different
health status. Meditation is a complementary therapy
posited to improve quality of life. Our aim is to compare
the performance of SF-12 and RAND-12 summary scores
in a sample of people practicing meditation. METHODS:
Data from a convenience sample of 141 subjects practic-
ing meditation were abstracted from a larger, cross-
sectional study. Generalized linear models were used to
compare physical and mental summary scores of the SF-
12 (PCS12 and MCS12) and RAND-12 (PHC and MHC)
adjusted for age, gender, education, and income among
known groups deﬁned by quartiles of: 1) number of co-
morbidities, 2) overall quality of life (VAS-QOL); and 3)
meditation practice time. RESULTS: Compared to the
general population, the subjects had comparable physi-
cal and mental summary scores. As anticipated, all the
summary scores (PCS12, MCS12, PHC, and MHC)
decreased with the increasing number of co-morbidities,
and increased with increasing VAS-QOL and meditation
time. All measures were signiﬁcantly different across
groups deﬁned by number of co-morbidities (p < .05)
while the MHC had the highest relative validity (F3,118
= 7.65, p < .001). Furthermore, the MHC was the only
measure to distinguish subjects grouped by VAS-QOL (p
= .01) or meditation time (p = .09). Correlation between
PHC and MHC was small and positive (r = .246, p < .01).
However, correlation between PCS12 and MCS12 was
negative (r = -.384, p < .01) which is inconsistent with
the assumption of no correlation which forms the basis
of the SF-12 algorithm. CONCLUSIONS: Our study
shows the RAND-12 summary scores are more sensitive
in detecting differences in mental health among people
practicing meditation. Moreover, the use of SF-12
summary scores may be problematic because of the coun-
terintuitive correlation between the two scores and the
RAND-12 summary scores may be a better alternative.
PMH50
COMORBID DIABETES AND SCHIZOPHRENIA:
IMPACT ON HEALTHCARE RESOURCE USE
Mackell JA,Warrington LE, Loebel A
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: We compared the use of healthcare
resources in patients with schizophrenia alone, com-
orbid diabetes and schizophrenia, and diabetes alone.
METHODS: In June 2002, 850 people with schizophre-
nia, identiﬁed through the National Alliance for the Men-
tally Ill and community mental health centers, completed
self-administered questionnaires. Of these, 109 (12.8%)
reported comorbid diabetes. For comparison, a random
sample of 1000 persons with type 2 diabetes (18 to 64
years old) was generated from a similar study of 4721
people with diabetes. Data on emergency room (ER) visits
and hospitalization during the past six months were col-
lected for all respondents. Costs were calculated using
Statistical Abstracts of the United States: 2000 (ER:
$320/visit; hospitalization: $1126/day). Gender, age, and
race were controlled using multiple regression analysis.
RESULTS: Patients with schizophrenia averaged 3.3 days
more hospitalized (P = 0.004) than patients with diabetes
alone (additional cost: $3700). Patients with comorbid
schizophrenia and diabetes averaged 1.2 ER visits more
(P < 0.001) and 11.3 days more hospitalized (P < 0.001)
than patients with diabetes alone (additional costs: $396
and $12,800, respectively), and 1.0 ER visit more (P =
0.001) and 8.1 days more hospitalized (P > 0.001) than
respondents with schizophrenia alone (additional costs:
$319 and $9100, respectively). CONCLUSION: Comor-
bid schizophrenia and diabetes are associated with sig-
niﬁcantly greater healthcare resource use and costs of care
than either diabetes or schizophrenia alone.
PMH51
IMPACT OF COMORBID DIABETES ON
FUNCTIONING IN SCHIZOPHRENIA
Mackell JA,Warrington LE, Loebel A
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: Use of conventional and atypical antipsy-
chotics in persons with schizophrenia has been associated
with increased risk of developing type 2 diabetes. We
studied the potential link between comorbid diabetes 
and functional status in persons with schizophrenia.
METHODS: In June 2002, 850 people with schizophre-
nia, identiﬁed through the National Alliance for the Men-
tally Ill and community mental health centers, completed
self-administered questionnaires. Of these, 109 (12.8%)
respondents had diabetes. Subjects were asked how many
hours per week they typically engaged in paid employ-
ment, volunteer work, or school/college work. Those who
participated in at least one of these activities were con-
sidered to engage in productive activity. Gender, age, and
race were controlled using multiple regression analysis for
hours per week of productive activity and logistic regres-
sion for participation in productive activity. RESULTS:
Compared with those with diabetes, respondents without
diabetes were 1.97 (P = 0.002) times as likely to partici-
pate in productive activities. Paid employment was 2.57
(P < 0.001) times more likely; volunteer work, 1.56 (P =
0.073) times more likely; and school/college work, 7.32
(P < 0.001) times more likely. Respondents without dia-
betes averaged 12.41 (P < 0.001) more hours per week of
productive activity than those with diabetes. CONCLU-
SION: Among people with schizophrenia, comorbid dia-
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betes has a negative impact on functioning as measured
by engagement in productive activities.
PMH52
PATIENT-VALUED HEALTH STATE UTILITIES
FOR BIPOLAR DISORDER: DIFFERENCES THAT
CAN BE MEASURED
Hanlon JT1, Mannix S1, Kleinman L1, Martin S2, Revicki D1
1MEDTAP International, Inc, Bethesda, MD, USA; 2J&J
Pharmaceuticals Services, L.L.C, Raritan, NJ, USA
OBJECTIVE: Patients with bipolar disorder experience
problems with functioning and well-being, or health
related quality of life (HRQL). Utilities, reﬂecting the
impact of psychopathology and treatment on patient
HRQL, are needed to estimate outcomes in economic
evaluations. Our objective was to elicit utility scores for
health states associated with bipolar disorder and side-
effects of treatment. METHODS: Patients with a DSM-
IV deﬁned diagnosis of Bipolar I Disorder who were
currently stable, but had experienced two previous manic
or mixed episodes in the last ﬁve years, were recruited
and interviewed at three clinical research sites in the US.
Health states used in the interview were derived from lit-
erature, clinical experience and clinical trial data. They
included attributes of clinical psychopathology (stable,
mania or major depression), HRQL (physical, social, and
role functioning), treatment-related side effects, and treat-
ment setting (inpatient or outpatient). In a one-time stan-
dard gamble interview, each patient valued a subset of the
total number of health states. RESULTS: Inpatient mania
mean utility scores for moderate severity, ranged from
0.14 (S.D. 0.20) to 0.37 (S.D. 0.33) and for mild sever-
ity, utility scores ranged from 0.13 (S.D. 0.16) to 0.83
(S.D. 0.21). Utility scores for outpatient mania, moderate
severity, ranged from 0.15 (S.D. 0.19) to 0.60 (S.D. 0.07)
and for mild severity scores ranged from 0.79 (S.D. 0.11)
to 0.36 (S.D. 0.16). Stable state scores ranged from 0.36
(S.D. 0.16) to 0.95 (S.D. 0.00) and depression was 0.30
(S.D. 0.33). Treatment related side-effects appear to
decrease patient utilities and have a larger impact in stable
states. CONCLUSIONS: Health state utility scores can be
obtained from patients with bipolar disorder. The utility
scores provided by patients for hypothetical states
demonstrate differences by disease severity and treatment.
PMH53
IMPACT OF WEIGHT GAIN ON HEALTH-
RELATED QUALITY OF LIFE (HRQL) OF
BIPOLAR PATIENTS
Bolge SC1, Meletiche DM2
1Consumer Health Sciences, Princeton, NJ, USA; 2Janssen
Pharmaceutica, Inc,Titusville, NJ, USA
OBJECTIVES: To determine whether patients with
bipolar disorder with weight gain have different HRQL
than those without weight gain. METHODS: In June
2001, 573 persons reported being diagnosed with bipolar
disorder on a self-administered questionnaire. Of these,
377 provided information on their weight gains or losses
during the past six months. A cross-sectional comparison
of the HRQL among patients with bipolar disorder who
gained weight and those who did not was performed.
Weight gain was deﬁned as gaining six or more pounds
(2.73Kg) over the past six months. HRQL was measured
using two validated scales, the Psychological General
Well-Being scale (PGWB) and the SF-8. RESULTS: Out
of 377 patients included in the analysis, 168 (44.6%)
reported weight gain. Patients who reported weight gain
had signiﬁcantly lower mean PGWB scores, 47.4 (SD =
21.9) vs. 53.2 (SD = 23.6) p = 0.015 and lower scores on
Anxiety, Self-Control and Vitality subscales compared to
those without weight gain. Patients with weight gain had
statistically lower scores in the mental health summary
scale, and the role emotional and mental health domains
of the SF-8. CONCLUSION: Patients with bipolar dis-
order and weight gain appear to have a lower HRQL
compared to patients without weight gain.
PMH54
MENTAL HEALTH COMORBIDITY PREVALENCE,
PATTERNS,AND IMPACT ON QUALITY OF LIFE
AMONG GULF WAR VETERANS
Forman VL1, Carney CP1, Peloso P1,Woolson RF2,
Black DW1, Doebbeling BN1
1University of Iowa, Iowa City, IA, USA; 2Medical University of
South Carolina, Charleston, SC, USA
OBJECTIVES: Comorbid mental health conditions are
common and associated with poor health outcomes in the
U.S. population. The purpose of this study is to examine
the prevalence and patterns of mental health comorbid-
ity and whether comorbidity inﬂuences quality of life
ratings in a sample of Gulf War military personnel.
METHODS: The Iowa Gulf War Study Case Validation
study conducted face-to-face evaluations of 602 military
personnel either deployed or eligible but not deployed to
the Persian Gulf War (PGW) in 1999–2002 to estimate
the magnitude of health problems encountered by the
PGW deployed. The subjects were sampled by conduct-
ing a series of case-control studies nested within a popu-
lation-based survey of 4886 military personnel (JAMA,
1997). Mental health comorbidity consisted of endorsing
two or more mental disorders. We used the Health Util-
ities Index (HUI) to measure health-related quality of life
(HRQoL). RESULTS: One hundred ninety-three (32%)
of the 602 surveyed veterans had a current mental disor-
der. Slightly over 11% (n = 69) had a comorbid mental
disorder. The most common patterns of comorbidity were
co-occurring depressive and anxiety disorders, followed
by co-occurring substance use, depressive, and anxiety
disorders. Those with mental health comorbidity had
lower HUI scores than veterans without mental health
